Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

Easton J. D., Aunes M., Albers G. W., Amarenco P., Bokelund-Singh S., Denison H., ...Daha Fazla

CIRCULATION, cilt.136, sa.10, ss.907-934, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 136 Sayı: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1161/circulationaha.117.028566
  • Dergi Adı: CIRCULATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.907-934
  • Anahtar Kelimeler: aspirin, hemorrhage, ischemic attack, transient, platelet aggregation inhibitors, stroke, P2Y(12) RECEPTOR ANTAGONIST, DOUBLE-BLIND, CLOPIDOGREL, INHIBITION, PREVENTION, RATIONALE, AZD6140, PLACEBO, DESIGN, MATCH
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH).